Published in Clin Pharmacol Ther on February 01, 1982
Polydrug abuse: a review of opioid and benzodiazepine combination use. Drug Alcohol Depend (2012) 1.85
Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol (1999) 1.33
Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study. Eur J Clin Pharmacol (2009) 0.78
Parent and Metabolite Opioid Drug Concentrations in Unintentional Deaths Involving Opioid and Benzodiazepine Combinations. J Forensic Sci (2015) 0.75
Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med (2000) 5.12
Nicotine metabolism and intake in black and white smokers. JAMA (1998) 5.03
Smokers of low-yield cigarettes do not consume less nicotine. N Engl J Med (1983) 4.80
Improved gas chromatographic method for the determination of nicotine and cotinine in biologic fluids. J Chromatogr (1981) 3.72
Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control (1998) 3.47
Cotinine disposition and effects. Clin Pharmacol Ther (1983) 3.26
Nicotine absorption and cardiovascular effects with smokeless tobacco use: comparison with cigarettes and nicotine gum. Clin Pharmacol Ther (1988) 3.05
Influence of smoking fewer cigarettes on exposure to tar, nicotine, and carbon monoxide. N Engl J Med (1986) 2.87
Cannabinoid-opioid interaction in chronic pain. Clin Pharmacol Ther (2011) 2.75
Elimination of cotinine from body fluids: implications for noninvasive measurement of tobacco smoke exposure. Am J Public Health (1988) 2.63
Drug interactions with tobacco smoking. An update. Clin Pharmacokinet (1999) 2.52
Apparent underreporting of cigarette consumption among Mexican American smokers. Am J Public Health (1990) 2.47
Daily intake of nicotine during cigarette smoking. Clin Pharmacol Ther (1984) 2.43
Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther (1994) 2.41
Dose-responses from multi-model inference for the non-cancer disease mortality of atomic bomb survivors. Radiat Environ Biophys (2012) 2.31
Nicotine and cotinine elimination pharmacokinetics in smokers and nonsmokers. Clin Pharmacol Ther (1993) 2.30
Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther (1994) 2.28
Amanita phalloides-type mushroom poisoning. West J Med (1982) 2.26
The pharmacogenetics research network: from SNP discovery to clinical drug response. Clin Pharmacol Ther (2007) 2.18
Cotinine in the serum, saliva, and urine of nonsmokers, passive smokers, and active smokers. Am J Public Health (1988) 2.16
The correlation of age of onset with CTG trinucleotide repeat amplification in myotonic dystrophy. J Med Genet (1992) 2.15
Ethnic differences in N-glucuronidation of nicotine and cotinine. J Pharmacol Exp Ther (1999) 2.14
Interindividual variability in the metabolism and cardiovascular effects of nicotine in man. J Pharmacol Exp Ther (1982) 2.12
Selected ion monitoring method for determination of nicotine, cotinine and deuterium-labeled analogs: absence of an isotope effect in the clearance of (S)-nicotine-3',3'-d2 in humans. Biol Mass Spectrom (1991) 2.10
Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Mol Psychiatry (2006) 1.89
Nicotine blood levels and subjective craving for cigarettes. Pharmacol Biochem Behav (2000) 1.87
Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend (1993) 1.84
Risks and benefits of nicotine to aid smoking cessation in pregnancy. Drug Saf (2001) 1.84
Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther (2009) 1.83
Is serum cotinine a better measure of cigarette smoking than self-report? Prev Med (1995) 1.82
Clonidine for smoking cessation. Cochrane Database Syst Rev (2004) 1.80
Misclassification of smoking status by self-reported cigarette consumption. Am Rev Respir Dis (1992) 1.79
Clinical pharmacokinetics of lignocaine. Clin Pharmacokinet (1978) 1.79
Inhibition of plasma membrane monoamine transporters by beta-ketoamphetamines. Eur J Pharmacol (1999) 1.73
Vaporization as a smokeless cannabis delivery system: a pilot study. Clin Pharmacol Ther (2007) 1.70
Prognostic significance of angiographically documented left ventricular aneurysm from the Coronary Artery Surgery Study (CASS). Am J Cardiol (1982) 1.65
Prospective multicenter evaluation of colon capsule examination indicated by colonoscopy failure or anesthesia contraindication. Endoscopy (2012) 1.63
Circadian blood nicotine concentrations during cigarette smoking. Clin Pharmacol Ther (1982) 1.60
Fluoxetine for cocaine dependence in methadone maintenance: quantitative plasma and urine cocaine/benzoylecgonine concentrations. J Clin Psychopharmacol (1993) 1.60
Reducing tobacco addiction through tobacco product regulation. Tob Control (2004) 1.59
Randomized study of the treatment of phenobarbital overdose with repeated doses of activated charcoal. JAMA (1984) 1.58
Nicotine patch therapy in smoking cessation reduces the extent of exercise-induced myocardial ischemia. J Am Coll Cardiol (1997) 1.56
Preliminary observations on the effects of age on oropharyngeal deglutition. Dysphagia (1989) 1.53
Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther (1997) 1.53
Toward a comprehensive long term nicotine policy. Tob Control (2005) 1.52
Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health (1999) 1.52
Cigarette smoking, nicotine, and body weight. Clin Pharmacol Ther (2011) 1.52
Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulfaphenazole. Clin Pharmacol Ther (1977) 1.49
Adequacy of "hot biopsy" for the treatment of diminutive polyps: a prospective randomized trial. Am J Gastroenterol (1989) 1.49
Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med (1989) 1.48
Reduced tar, nicotine, and carbon monoxide exposure while smoking ultralow- but not low-yield cigarettes. JAMA (1986) 1.45
Determinants of nicotine intake while chewing nicotine polacrilex gum. Clin Pharmacol Ther (1987) 1.45
Deficient C-oxidation of nicotine. Clin Pharmacol Ther (1995) 1.43
The dopamine transporter gene and Parkinson's disease in a Chinese population. Neurology (1997) 1.43
Poisoning due to calcium antagonists. Experience with verapamil, diltiazem and nifedipine. Drug Saf (1992) 1.43
Prenatal nicotine exposure alters pulmonary function in newborn rhesus monkeys. Am J Respir Crit Care Med (2001) 1.42
Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol (1982) 1.41
Changes in plasma catecholamines after tonic-clonic seizures. Neurology (1984) 1.40
The use of biologic fluid samples in assessing tobacco smoke consumption. NIDA Res Monogr (1983) 1.39
Management of theophylline overdose patients in the intensive care unit. Anaesth Intensive Care (1992) 1.39
Phencyclidine poisoning. JAMA (1975) 1.37
Diagnosis and treatment of Amanita phalloides-type mushroom poisoning: use of thioctic acid. West J Med (1976) 1.36
A proposal to develop meaningful labeling for cigarettes. JAMA (1994) 1.35
Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther (1985) 1.35
Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. Br J Clin Pharmacol (1991) 1.34
Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol (1997) 1.32
Plasma nicotine and cotinine concentrations in habitual smokeless tobacco users. Clin Pharmacol Ther (1981) 1.31
Amatoxin poisoning in northern California, 1982-1983. West J Med (1986) 1.31
Recent studies of nicotine metabolism in humans. Pharmacol Biochem Behav (1988) 1.30
Methamphetamine and ethanol interactions in humans. Clin Pharmacol Ther (1995) 1.28
Nicotine metabolism and elimination kinetics in newborns. Clin Pharmacol Ther (2000) 1.26
Clinical pharmacology of nicotine. Annu Rev Med (1986) 1.25
Nicotine exposure among nondependent smokers. Arch Gen Psychiatry (1990) 1.24
A reordering of human chromosome 19 long-arm DNA markers and identification of markers flanking the myotonic dystrophy locus. Genomics (1989) 1.24
Failure of haemoperfusion and haemodialysis to prevent death in paraquat poisoning. A retrospective review of 42 patients. Med Toxicol Adverse Drug Exp (1988) 1.23
Bioavailability of sublingual buprenorphine. J Clin Pharmacol (1997) 1.21
Post-Chornobyl thyroid cancers in Ukraine. Report 1: estimation of thyroid doses. Radiat Res (2005) 1.20
Altered patterns of drug metabolism in patients with acquired immunodeficiency syndrome. Clin Pharmacol Ther (1993) 1.20
Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol (1996) 1.18
Trans-3'-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. Br J Clin Pharmacol (2001) 1.17
Sources of variability in nicotine and cotinine levels with use of nicotine nasal spray, transdermal nicotine, and cigarette smoking. Br J Clin Pharmacol (1997) 1.17
Effects of cigarette smoking and its cessation on lipid metabolism and energy expenditure in heavy smokers. J Clin Invest (1994) 1.16